ESSA Pharma — Company Overview, News & Financial Data

ESSA Pharma (NASDAQ:EPIX) is a biopharmaceutical entity focused on developing novel therapies for the treatment of prostate cancer. Its operations revolve around the research and development of small molecule drugs aimed at disrupting the androgen receptor signaling pathway, a critical target in the fight against this prevalent cancer. ESSA Pharma's projects include the advancement of its leading candidate, EPI-7386, through various stages of clinical trials with the goal of offering a new therapeutic option for patients with castration-resistant prostate cancer. The company's objectives are centered on bringing innovative treatments to market, addressing unmet medical needs, and improving the quality of life for individuals battling prostate cancer.